换一批Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
第一作者：
C,Skedgel
第一单位：
Department of Medicine, Centre for Clinical Research, Dalhousie University, 5790 University Ave, B3H 1V7, Halifax, NS, Canada. chris.skedgel@cdha.nshealth.ca
作者：
医学主题词
老年人(Aged);雄二烯类(Androstadienes);抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);芳香酶抑制剂(Aromatase Inhibitors);乳腺肿瘤(Breast Neoplasms);化学疗法, 辅助(Chemotherapy, Adjuvant);费用效益分析(Cost-Benefit Analysis);无病生存(Disease-Free Survival);用药计划表(Drug Administration Schedule);药费支出(Drug Costs);女(雌)性(Female);人类(Humans);Markov链(Markov Chains);中年人(Middle Aged);模型, 经济学(Models, Economic);肿瘤复发, 局部(Neoplasm Recurrence, Local);腈类(Nitriles);绝经后期(Postmenopause);质量校正寿命(Quality-Adjusted Life Years);他莫昔芬(Tamoxifen);治疗结果(Treatment Outcome);三唑类(Triazoles);美国(United States)
DOI
10.1007/s10549-006-9299-4
PMID
16897433
发布时间
2019-12-10
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
